Compare Adaptive Biotechnologies Corp (ADPT) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wheaton Precious Metals Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.05 (market cap $4.04B), while Wheaton Precious Metals Corp trades at $135.8 (market cap $60.94B). The key difference: Wheaton Precious Metals Corp is far larger — about 15.1× Adaptive Biotechnologies Corp's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WPM | |
|---|---|---|
Market Cap | $4.04B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $25.45 | $165.72 |
52-Week Low | $12.30 | $91.02 |
Enterprise Value | $4.10B | $62.82B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Wheaton Precious Metals (WPM) trades at $133.39, down 0.6% for the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.19, supported by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income reaching $1.47 billion, reflecting robust profitability margins.
The outlook remains positive with an 80% analyst buy rating and a $161.75 consensus price target, indicating ~21% upside. Key risks include reliance on commodity prices and projected negative cash flow in 2026. The stock's premium valuation (P/E 29.82) requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
